Venaxis upgraded to Buy from Hold at Canaccord
Canaccord believes Venaxis' is on track for the first FDA approved blood test aiding in identifying patients at low risk for appendicitis. Price target raised to $7 from $2.50.
Advertisement
Recommended Stories
Suze Orman Decided To Drop Homeowners Insurance After An Outrageous Quote: '$28,000 For A 2,100-Square-Foot Condo. Are You Kidding Me?'
Finance expert Suze Orman has voiced concerns about the impact of climate change on property insurance costs, asserting it could threaten the American dream of homeownership. Orman, 72, faced a $28,000 annual insurance quote for her Florida oceanside condo, leading her to forego coverage entirely. She highlights a troubling trend where soaring insurance costs driven by frequent and severe weather events may deter Americans from buying homes. Don't Miss: For many first-time buyers, a house is abo
Benzinga•The IRS says it’s going after wealthy tax cheats. Here’s what new audit stats show.
After Congress approved billions of extra funding for tax compliance, the Internal Revenue Service pledged it would get tougher on rich taxpayers and corporations while avoiding extra scrutiny of middle-class households.
MarketWatch•Analysts revise Facebook parent Meta stock price targets before earnings
Here's what could happen next to Meta Platforms' stock.
TheStreet•JPMorgan’s ‘Bloody Friday’: Why Several Top Financial Advisors Jumped Ship the Same Day
Six teams managing nearly $15 billion in total assets quit JPMorgan Chase’s brokerage unit to join competitors last Friday. Here’s what may have triggered their departures.
Barrons.com•Advanced Micro Devices (AMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Advanced Micro (AMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks•Holding 6 Ethereum (ETH) Could Make You A Millionaire, According to Cathie Wood
With the recent halving and spot exchange-traded funds (ETFs) driving demand, Bitcoin has had the spotlight for much of 2024. However, according to Cathie Wood of Ark Invest, Ethereum (ETH) could catch up to Bitcoin and provide investors with huge profits in the coming years. At an investor conference held by Ark Invest, Wood spoke about Ethereum, noting that the project could reach a market capitalization of $20 trillion by 2032. ETH currently has a supply of around 120 million tokens. So, a ma
Benzinga•Ex-Googler and Palestinian-American fired for opposing Project Nimbus speaks out: ‘This was not my idea of what the American workplace should be’
Several fired Google employees spoke at a press conference Monday about their experiences.
Fortune•3 Super-Safe Stocks That Could Reach 70 Consecutive Years of Dividend Raises By 2032
When it comes to reliable passive income, these three dividend-paying companies are best in breed.
Motley Fool•Should You Buy Intel Stock Before Earnings?
Intel is underperforming the broader semiconductor index.
Motley Fool•Forget Nvidia: Billionaires Are Selling It and Buying These 2 High-Octane Artificial Intelligence (AI) Growth Stocks Instead
Billionaire investors are ditching the "infrastructure backbone" of the artificial intelligence (AI) revolution in favor of two industry-leading, irreplaceable AI stocks.
Motley Fool•